Dr. Afshin Dowlati, MD

Dr. Dowlati practices at University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System.

Dr. Dowlati's NPI, 1528084852, was assigned on July 13, 2006. Dr. Dowlati holds Ohio license 35-076391.

Dr. Dowlati's primary practice is University Hospitals Cleveland Medical Center, at 11100 Euclid Avenue, Cleveland, OH 44106 in Cuyahoga County. The practice phone is (216) 844-1000.

Dr. Dowlati's primary practice is University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System. Dr. Dowlati is also affiliated with University Hospitals Ahuja Medical Center. The medical group on file is University Hospitals Medical Practices. Dmand AI also links Dr. Dowlati to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dowlati practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Dowlati's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Dowlati is licensed in Ohio.

CMS data shows 338 Medicare services from Dr. Dowlati across 4 procedure codes in 2024, for 139 Medicare patients. Medicare paid $32,263 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 139 Medicare patients who saw Dr. Dowlati in 2024. The largest group is 65 to 74, with 74 patients. 75% of them have cancer, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.44, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dowlati's median patient age at 73, with 58% women.

In 2024, Dr. Dowlati wrote 351 Medicare Part D claims for 79 patients. 78% of them were for generic drugs. CMS names the drug for 229 of them, across 8 drugs with 11 or more claims each, at $928,279 in total drug cost. In 2023, CMS named 52 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Dowlati for performance year 2024, reported as part of a group. Dr. Dowlati accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dowlati as offering telehealth.

Dmand AI links 165 papers to Dr. Dowlati, published from 2006 to 2025. 2021 was the busiest year, with 17. The most frequent topics are Lung Neoplasms, Small Cell Lung Carcinoma and Carcinoma, Non-Small-Cell Lung. Dr. Dowlati has published most often in J Thorac Oncol. Dr. Dowlati's most frequent co-authors are Neelesh Sharma, MD, PhD, Charles M. Rudin, MD, PhD and Tithi Biswas, MD.

Dmand AI links Dr. Dowlati to 11 clinical trials, 5 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Biliary Tract Neoplasms, Esophageal Squamous Cell Carcinoma and Neoplasm Metastasis. National Cancer Institute (NCI) sponsors the most, 2. Open Payments lists research payments to Dr. Dowlati that name 2 trials.

CMS Open Payments shows 156 general payments to Dr. Dowlati from 27 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 87% of the total. AstraZeneca Pharmaceuticals LP paid the most, $53,207. It also lists 17 research payments totaling $15,259 from 2016 to 2025, naming 2 clinical trials.